Acerus terminates Natesto agreement with Endo
Acerus's immediate focus is to find a new Natesto partner in the US.
Acerus Pharmaceuticals Corporation has announced that the agreement with Endo Ventures Bermuda Limited (an affiliate of Endo International plc) relating to the commercialization of Natesto in the US and Mexico will be terminated, effective 30 June 2016.
Under the terms of the agreement with Acerus, Endo will continue to sell and distribute Natesto in the US until the effective date of termination.
Natesto is the first and only testosterone nasal gel to be approved and launched in the US for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
“While we are disappointed with Endo’s previously announced strategic business decision to realign their US branded resources from urology retail to their pain franchise, we are fully committed to the continued success of Natesto in the US,” said Tom Rossi, President and Chief Executive Officer of Acerus. “Our immediate focus is on finding a new Natesto partner in the US, the largest market for testosterone replacement therapy. We are encouraged by the positive physician and patient feedback received on the product to date, and believe there will be strong interest from other companies to step in and continue to drive the launch of Natesto.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.